| Alemtuzumab | Campath® | NHL - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Therapy for relapsed or refractory disease as a single agent or in combination with - chlorambucil with or without prednisone
- CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) in patients who are not able to tolerate fludarabine therapy
- fludarabine with or without cyclophosphamide
|
| Bevacizumab | Avastin® | Pancreatic Adenocarcinoma | Bevacizumab in combination with gemcitabine for locally advanced or metastatic disease |
| Carboplatin | Paraplatin® Injection | Breast Cancer - Invasive | Carboplatin in combination with docetaxel as a preferred treatment regimen for use in combination with trastuzumab for patients with recurrent or metastatic breast cancer |
| Carmustine | BiCNU® | NHL - Nongastric MALT Lymphoma | Second-line therapy for recurrent (stage IE-II) or progressive disease in candidates for high-dose therapy with autologous stem cell rescue (HDT/ASCR) as a component of miniBEAM regimen (carmustine, etoposide, cytarabine and melphalan) regimen with or without rituximab |
| Carmustine | BiCNU® | NHL - Follicular Lymphoma | Second-line therapy for refractory or progressive disease as a component of miniBEAM (carmustine, etoposide, cytarabine, and melphalan) regimen with or without rituximab |
| Carmustine | BiCNU® | NHL - Gastric MALT Lymphoma | Second-line therapy for recurrent or progressive disease in candidates for high-dose therapy with autologous stem cell rescue (HDT/ASCR) as a component of miniBEAM regimen (carmustine, etoposide, cytarabine and melphalan) with or without rituximab |
| Cetuximab | Erbitux® | Pancreatic Adenocarcinoma | Cetuximab in combination with gemcitabine for locally advanced or metastatic disease |
| Cisplatin | Platinol®, Platinol®-AQ | Uterine Neoplasms - Uterine Sarcoma | Single-agent therapy for advanced or metastatic disease |
| Cisplatin | Platinol®, Platinol®-AQ | Uterine Neoplasms - Uterine Sarcoma | Combination regimen cisplatin/ifosfamide/mesna for advanced or metastatic disease |
| Cytarabine | Cytosar-U® | Chronic Myelogenous Leukemia (CML) | Cytarabine in combination with interferon for patients not responding to imatinib |
| Dexamethasone; Dexamethasone sodium phosphate | None | Central Nervous System Cancers - Primary Central Nervous System Tumors | Consider systemic and/or intrathecal treatment in combination with a platinum agent and high-dose cytarabine for progressive or recurrent nonimmunosuppressed primary central nervous system lymphoma in patients with prior whole brain radiation therapy |
| Dexamethasone; Dexamethasone sodium phosphate | None | Central Nervous System Cancers - Primary Central Nervous System Tumors | Treatment in combination with a platinum agent and high-dose cytarabine and with radiation therapy for progressive nonimmunosuppressed primary central nervous system lymphoma in patients with a short or no response to prior methotrexate-based regimen without prior radiation therapy |
| Docetaxel | Taxotere® | Bladder Cancer | Chemotherapy in combination with gemcitabine with or without cisplatin for patients with muscle-invasive disease with local recurrence following bladder-sparing treatment in nonsurgical candidates or with or without radiation for patients with metastatic disease or for muscle-invasive disease with local recurrence following cystectomy |
| Docetaxel | Taxotere® | Non-Small Cell Lung Cancer (NSCLC) | Adjuvant chemotherapy in combination with carboplatin or gemcitabine. |
| Doxorubicin hydrochloride | None | Non-Melanoma Skin Cancers - Merkel Cell Carcinoma | Treatment for distant metastatic disease or disseminated recurrence with or without surgery or radiation therapy as a single agent or in combination with carboplatin or cisplatin (with or without etoposide) |
| Doxorubicin hydrochloride | None | Multiple Myeloma | Primary induction therapy in VAD (vincristine, doxorubicin, and dexamethasone) regimen for transplant candidates |
| Etoposide; Etoposide phosphate | Etopophos® Preservative Free, VePesid® | Small Cell Lung Cancer (SCLC) | Initial treatment in combination with cyclophosphamide and doxorubicin for extensive stage disease |
| Fluorouracil | None | Hepatobiliary Cancers - Gallbladder Cancer | Primary treatment in combination with gemcitabine for patients with unresectable disease with jaundice or metastatic disease |
| Fluorouracil | None | Rectal Cancer | Adjuvant concurrent chemoradiation therapy as a single agent for patients with T2, NX, margin-negative disease following transanal excision |
| Gefitinib | Iressa® | Non-Small Cell Lung Cancer (NSCLC) | Gefitinib as third-line therapy |
| Gemcitabine hydrochloride | Gemzar® | Central Nervous System Cancers - Metastatic Central Nervous System Lesions | Gemcitabine for melanoma metastatic brain tumors |
| Gemcitabine hydrochloride | Gemzar® | Hepatobiliary Cancers - Intrahepatic Cholangiocarcinoma | Adjuvant treatment in concurrent chemoradiation |
| Gemcitabine hydrochloride | Gemzar® | Non-Small Cell Lung Cancer (NSCLC) | Adjuvant chemotherapy in combination with carboplatin or docetaxel. |
| Ifosfamide | None | Small Cell Lung Cancer (SCLC) | Ifosfamide-based regimens as additional regimens |
| Ifosfamide | None | Uterine Neoplasms - Uterine Sarcoma | Combination regimen cisplatin/ifosfamide/mesna for advanced or metastatic disease |
| Interferon alfa-2a, recombinant | Roferon®-A | Chronic Myelogenous Leukemia (CML) | Interferon as standard first-line therapy |
| Interferon alfa-2a, recombinant | Roferon®-A | Chronic Myelogenous Leukemia (CML) | Interferon plus or minus cytarabine for patients not responding to imatinib |
| Interferon alfa-2b, recombinant | Intron®-A | Chronic Myelogenous Leukemia (CML) | Interferon as standard first-line therapy |
| Interferon alfa-2b, recombinant | Intron®-A | Chronic Myelogenous Leukemia (CML) | Interferon plus or minus cytarabine for patients not responding to imatinib |
| Interferon alfa-2b, recombinant | Intron®-A | Hepatobiliary Cancers - Hepatocellular Carcinoma | Treatment for selected low-risk hepatitis C patients with completely resected tumors and good performance status |
| Levoleucovorin | Fusilev™ | Esophageal Cancer | Indicated in combination with infusional fluorouracil-based regimens for preoperative and definitive chemoradiation and for locally advanced or metastatic disease |
| Melphalan; Melphalan hydrochloride | Alkeran® for injection, Alkeran® tablets | NHL - Nongastric MALT Lymphoma | Second-line therapy for recurrent (stage IE-II) or progressive disease in candidates for high-dose therapy with autologous stem cell rescue (HDT/ASCR) as a component of miniBEAM regimen (carmustine, etoposide, cytarabine and melphalan) with or without rituximab |
| Melphalan; Melphalan hydrochloride | Alkeran® for injection, Alkeran® tablets | NHL - Gastric MALT Lymphoma | Second-line therapy for recurrent or progressive disease in candidates for high-dose therapy with autologous stem cell rescue (HDT/ASCR) as a component of miniBEAM regimen (carmustine, etoposide, cytarabine and melphalan) with or without rituximab |
| Melphalan; Melphalan hydrochloride | Alkeran® for injection, Alkeran® tablets | NHL - Follicular Lymphoma | Second-line therapy for refractory or progressive disease as a component of miniBEAM (carmustine, etoposide, cytarabine, and melphalan) regimen with or without rituximab |
| Mesna | Mesnex® Injection, Mesnex® Tablets | Uterine Neoplasms - Uterine Sarcoma | Combination regimen cisplatin/ifosfamide/mesna for advanced or metastatic disease |
| Methylprednisolone; Methylprednisolone acetate; Methylprednisolone sodium succinate | Solu-Medrol® | Central Nervous System Cancers - Metastatic Central Nervous System Lesions | Methylprednisolone as steroid therapy in metastatic spine tumors |
| Metoclopramide hydrochloride | Reglan® (injection), Reglan® (tablets) | Antiemesis | Metoclopramide plus or minus diphenhydramine for moderate emetic risk chemotherapy |
| Mitoxantrone hydrochloride | Novantrone® | Acute Myeloid Leukemia (AML) | As induction or postinduction therapy in combination with cytarabine for patients less than 60 years with no antecedent hematologic disease |
| Oxaliplatin | Eloxatin® | Pancreatic Adenocarcinoma | Oxaliplatin in combination with gemcitabine for locally advanced or metastatic disease |
| Paclitaxel | Taxol® | Bladder Cancer | Chemotherapy in combination with cisplatin and/or gemcitabine for patients with muscle-invasive disease with local recurrence following bladder-sparing treatment in nonsurgical candidates or with or without radiation for patients with metastatic disease or for muscle-invasive disease with local recurrence following cystectomy |
| Pamidronate disodium | Aredia® | Prostate Cancer | Treatment of bone metastases in patients with castration-recurrent prostate cancer |
| Porfimer sodium | Photofrin® | Esophageal Cancer | Photodynamic therapy for the primary treatment of Tis or T1a esophageal cancer |
| Topotecan; Topotecan hydrochloride | Hycamtin® Injection | Uterine Neoplasms - Uterine Sarcoma | Single-agent therapy for advanced or metastatic disease |
| Topotecan; Topotecan hydrochloride | Hycamtin® Injection | Non-Melanoma Skin Cancers - Merkel Cell Carcinoma | Adjuvant treatment as a single agent or in combination with cisplatin or carboplatin with or without radiation therapy in older patients with N+ disease |
| Warfarin sodium | Coumadin® tablets; Coumadin® for injection | Venous Thromboembolic Disease | Anticoagulation treatment of cancer patients following anticoagulation therapy failure (defined as extension of venous thromboembolism or new venous thromboembolism while on anticoagulation therapy) of factor Xa antagonist. Not used in the immediate phase of anticoagulation treatment |